Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Gilead Completes $7.8 Billion Acquisition of Arcellx | Contract Pharma

What are you searching for?

Sign in
Breaking News

Gilead Completes $7.8 Billion Acquisition of Arcellx

Aims to maximize the long-term potential of anito-cel, a potentially transformative treatment for patients with multiple myeloma.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Gilead Sciences has completed its acquisition of Arcellx, moving to consolidate ownership of an experimental CAR‑T therapy for multiple myeloma as it readies a potential U.S. launch.

Under the deal, Gilead paid $115 a share in cash plus a nontransferable $5 contingent value right tied to future sales, valuing Arcellx at about $7.8 billion at closing. The transaction gives Gilead full control of anitocabtagene autoleucel, or anito‑cel, a BCMA‑targeted CAR‑T therapy under regulatory review.

Arcellx shareholders will receive the contingent payment if anito‑cel generates at least $6 billion in cumulative global net sales through 2029. Arcellx becomes a wholly owned Gilead subsidiary and its shares will be delisted from Nasdaq.

Gilead said the acquisition is expected to be modestly dilutive to earnings in the near term and accretive beginning in 2028, subject to FDA approval of the therapy.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics